Published in Blood on October 16, 2012
Biology of tissue factor pathway inhibitor. Blood (2014) 1.01
Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor. Blood (2015) 0.93
Erythrocyte-derived microparticles supporting activated protein C-mediated regulation of blood coagulation. PLoS One (2014) 0.85
Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-α but not for cell surface-associated tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol (2013) 0.84
TFPI cofactor function of protein S: essential role of the protein S SHBG-like domain. Blood (2014) 0.78
Cellular expression and biological activities of alternatively spliced forms of tissue factor pathway inhibitor. Curr Opin Hematol (2013) 0.77
Protective effects of non-anticoagulant activated protein C variant (D36A/L38D/A39V) in a murine model of ischaemic stroke. PLoS One (2015) 0.76
Targeting TFPI for hemophilia treatment. Thromb Res (2016) 0.75
Essential role of the disintegrin-like domain in ADAMTS13 function. Blood (2009) 1.86
Expression of terminal alpha2-6-linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13. Blood (2009) 1.81
Multifunctional specificity of the protein C/activated protein C Gla domain. J Biol Chem (2006) 1.81
High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood (2011) 1.78
ADAMTS13 substrate recognition of von Willebrand factor A2 domain. J Biol Chem (2005) 1.76
A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood (2009) 1.51
Endothelial von Willebrand factor regulates angiogenesis. Blood (2010) 1.47
Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality. J Biol Chem (2002) 1.45
Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood (2004) 1.36
Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood (2011) 1.33
Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood (2005) 1.30
An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood (2009) 1.27
N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood (2007) 1.24
The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol (2007) 1.24
Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells. Blood (2013) 1.22
Reduced body weight and increased postimplantation fetal death in tyrosylprotein sulfotransferase-1-deficient mice. J Biol Chem (2002) 1.20
ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood (2006) 1.18
Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor. Blood (2009) 1.18
Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thromb Res (2003) 1.06
The importance of vicinal cysteines, C1669 and C1670, for von Willebrand factor A2 domain function. Blood (2010) 1.00
Mechanism of von Willebrand factor scissile bond cleavage by a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). Proc Natl Acad Sci U S A (2011) 0.98
Roles of low specificity and cofactor interaction sites on thrombin during factor XIII activation. Competition for cofactor sites on thrombin determines its fate. J Biol Chem (2003) 0.95
Oxidized phospholipids in oxidized low-density lipoprotein reduce the activity of tissue factor pathway inhibitor through association with its carboxy-terminal region. Antioxid Redox Signal (2004) 0.94
Selective modulation of protein C affinity for EPCR and phospholipids by Gla domain mutation. FEBS J (2005) 0.91
A functional calcium-binding site in the metalloprotease domain of ADAMTS13. Blood (2008) 0.91
Deletion of P1 arginine in a novel antithrombin variant (antithrombin London) abolishes inhibitory activity but enhances heparin affinity and is associated with early onset thrombosis. J Biol Chem (2003) 0.90
Naturally occurring mutations in the thrombomodulin gene leading to impaired expression and function. Blood (2002) 0.90
Mapping the N-glycome of human von Willebrand factor. Biochem J (2012) 0.90
Molecular diversity and thrombotic risk in protein S deficiency: the PROSIT study. Hum Mutat (2005) 0.90
O-linked glycosylation of von Willebrand factor modulates the interaction with platelet receptor glycoprotein Ib under static and shear stress conditions. Blood (2012) 0.87
Role of a 5'-enhancer in the transcriptional regulation of the human endothelial cell protein C receptor gene. Blood (2006) 0.87
The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity. Blood (2010) 0.87
Activated protein C cofactor function of protein S: a novel role for a γ-carboxyglutamic acid residue. Blood (2011) 0.86
Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for fetal death. Blood (2004) 0.86
Control of VWF A2 domain stability and ADAMTS13 access to the scissile bond of full-length VWF. Blood (2014) 0.85
Deletion or replacement of the second EGF-like domain of protein S results in loss of APC cofactor activity. Blood (2002) 0.83
Differential expression of Toll-like receptors in follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphoma. Exp Mol Pathol (2010) 0.83
Specific N-linked glycosylation sites modulate synthesis and secretion of von Willebrand factor. Blood (2010) 0.83
Vessel wall BAMBI contributes to hemostasis and thrombus stability. Blood (2014) 0.83
Protein S Gla-domain mutations causing impaired Ca(2+)-induced phospholipid binding and severe functional protein S deficiency. Blood (2002) 0.82
Efficient isolation of peptide ligands for the endothelial cell protein C receptor (EPCR) using candidate receptor phage display biopanning. Peptides (2005) 0.81
Tissue factor pathway inhibitor induces expression of JUNB and GADD45B mRNAs. Biochem Biophys Res Commun (2002) 0.81
Activated protein C cofactor function of protein S: a critical role for Asp95 in the EGF1-like domain. Blood (2010) 0.81
Genetic and phenotypic variability between families with hereditary protein S deficiency. Thromb Haemost (2002) 0.81
Anti-inflammatory effects of long-lasting locally-delivered human recombinant tissue factor pathway inhibitor after balloon angioplasty. Basic Res Cardiol (2002) 0.80
Binding of calcium to anticoagulant protein S: role of the fourth EGF module. Biochemistry (2006) 0.78
Oxidized low-density lipoprotein associates strongly with carboxy-terminal domain of tissue factor pathway inhibitor and reduces the catalytic activity of the protein. Thromb Haemost (2002) 0.78
Regulation of the human endothelial cell protein C receptor gene promoter by multiple Sp1 binding sites. Blood (2003) 0.77
Blocking direct inhibitor bleeding. Blood (2013) 0.77
Shear tango: dance of the ADAMTS13/VWF complex. Blood (2008) 0.77
Blocking VWF platelet binding to treat TTP. Blood (2012) 0.75
Third-harmonic-generation of a diode laser for quantum control of beryllium ions. Opt Express (2017) 0.75
Autoantibodies to thrombin directed against both of its cryptic exosites. Br J Haematol (2006) 0.75